» Articles » PMID: 21472005

IFN-γ Signaling, with the Synergistic Contribution of TNF-α, Mediates Cell Specific Microglial and Astroglial Activation in Experimental Models of Parkinson's Disease

Overview
Journal Cell Death Dis
Date 2011 Apr 8
PMID 21472005
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

To through light on the mechanisms underlying the stimulation and persistence of glial cell activation in Parkinsonism, we investigate the function of IFN-γ and TNF-α in experimental models of Parkinson's disease and analyze their relation with local glial cell activation. It was found that IFN-γ and TNF-α remained higher over the years in the serum and CNS of chronic Parkinsonian macaques than in untreated animals, accompanied by sustained glial activation (microglia and astroglia) in the substantia nigra pars compacta. Importantly, Parkinsonian monkeys showed persistent and increasing levels of IFN-γR signaling in both microglial and astroglial cells. In addition, experiments performed in IFN-γ and TNF-α KO mice treated with MPTP revealed that, even before dopaminergic cell death can be observed, the presence of IFN-γ and TNF-α is crucial for microglial and astroglial activation, and, together, they have an important synergistic role. Both cytokines were necessary for the full level of activation to be attained in both microglial and astroglial cells. These results demonstrate that IFN-γ signaling, together with the contribution of TNF-α, have a critical and cell-specific role in stimulating and maintaining glial cell activation in Parkinsonism.

Citing Articles

Malvidin-3-O-Glucoside Mitigates α-Syn and MPTP Co-Induced Oxidative Stress and Apoptosis in Human Microglial HMC3 Cells.

Sood R, Sanjay , Kang S, Yoon N, Lee H Int J Mol Sci. 2024; 25(23).

PMID: 39684444 PMC: 11641650. DOI: 10.3390/ijms252312733.


The microglial P2Y receptor as a therapeutic target for neurodegenerative diseases.

Dundee J, Brown G Transl Neurodegener. 2024; 13(1):47.

PMID: 39243044 PMC: 11380353. DOI: 10.1186/s40035-024-00438-5.


The Role of Astrocytes in Parkinson's Disease : Astrocytes in Parkinson's Disease.

Garcia R, Zarate S, Srinivasan R Adv Neurobiol. 2024; 39:319-343.

PMID: 39190081 DOI: 10.1007/978-3-031-64839-7_13.


Differentiation and regulation of CD4 T cell subsets in Parkinson's disease.

Sun X, Gu R, Bai J Cell Mol Life Sci. 2024; 81(1):352.

PMID: 39153043 PMC: 11335276. DOI: 10.1007/s00018-024-05402-0.


Exploring the therapeutic potential: Apelin-13's neuroprotective effects foster sustained functional motor recovery in a rat model of Huntington's disease.

Torkamani-Dordshaikh S, Darabi S, Norouzian M, Bahar R, Beirami A, Moghaddam M Anat Cell Biol. 2024; 57(3):419-430.

PMID: 39079710 PMC: 11424562. DOI: 10.5115/acb.23.284.


References
1.
Pott Godoy M, Tarelli R, Ferrari C, Sarchi M, Pitossi F . Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain. 2008; 131(Pt 7):1880-94. PMC: 2442423. DOI: 10.1093/brain/awn101. View

2.
Luchtman D, Shao D, Song C . Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav. 2009; 98(1-2):130-8. DOI: 10.1016/j.physbeh.2009.04.021. View

3.
Lung H, Leung K, Stadlin A, Ma C, Tsang D . Induction of tumor necrosis factor receptor type 2 gene expression by tumor necrosis factor-alpha in rat primary astrocytes. Life Sci. 2001; 68(18):2081-91. DOI: 10.1016/s0024-3205(01)00997-3. View

4.
Kopf M, Bachmann M, Marsland B . Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov. 2010; 9(9):703-18. DOI: 10.1038/nrd2805. View

5.
Damier P, Hirsch E, Agid Y, Graybiel A . The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999; 122 ( Pt 8):1437-48. DOI: 10.1093/brain/122.8.1437. View